Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
MBX Biosciences, Inc. Common Stock (MBX)
USD60.04
-1.01 (-1.65%)
US NASDAQ Healthcare Biotechnology
Address
11711 N. Meridian Street 46032
Carmel, IN, US
Carmel, IN, US
CEO
Peter Kent Hawryluk
Website
mbxbio.com
IPO
2000-01-14
CIK 1776111 ISIN US55287L1017
Description
MBX Biosciences, Inc. is a biopharmaceutical company in its clinical development phase, dedicated to pioneering precise peptide-based therapies for endocrine and metabolic conditions. Its most advanced drug candidate, MBX 2109, is a parathyroid hormone peptide prodrug currently in Phase 2 clinical trials. This medication is being evaluated as a long-duration hormone replacement treatment for individuals suffering from chronic hypoparathyroidism. The company is also progressing with MBX 1416, a prolonged-action glucagon-like peptide-1 (GLP-1) receptor antagonist, which is undergoing Phase 1 clinical assessment. The aim of this therapy is to address post-bariatric hypoglycemia, a persistent complication often seen after weight-loss surgery. Furthermore, MBX Biosciences is developing MBX 4291, a key candidate for obesity treatment. This highly potent and long-acting prodrug functions as a co-agonist for both GLP-1 and glucose-dependent insulinotropic polypeptide (GIP) receptors. It is currently in investigational new drug (IND)-enabling studies, with the intention of treating obesity and its associated health issues. Founded in 2018, the company's operations are headquartered in Carmel, Indiana.
News Sentiment (7d)
Based on only 1 article — low confidence
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
USD60.04
-1.01 (-1.65%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
761.9K
Beta
0.16
Float Shares
14.61M
Free Float %
43.5%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -7.73% | +15.56% | +19.29% | -2.68% | +50.33% | +17.25% | +231.96% | +56.36% | +56.36% | +56.36% | +56.36% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Analyst Consensus (5 ratings, all time)
Buy
Price Targets & DCF
Current price
60.04
Low
18.00
-70.0%
Consensus
60.33
+0.5%
Median
65.00
+8.3%
High
88.00
+46.6%
DCF (Unlevered)
2.02
-96.6%
DCF (Levered)
2.05
-96.6%
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
Ratings Trend (MoM)
92% Bullish
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 2 | 0 |
| Buy | 9 | 0 |
| Hold | 0 | 0 |
| Sell | 1 | 0 |
| Strong Sell | 0 | 0 |
Price Target Summary
| Period | # Analysts | Avg Target |
|---|---|---|
| Last Month | — | — |
| Last Quarter | 1 |
50.00
-16.7%
|
| Last Year | 7 |
52.86
-12.0%
|
| All Time | 8 |
51.75
-13.8%
|
Quality scores
Altman Z-Score
53.33
Safe zone
Piotroski F-Score
2 / 9
Weak
MOAT Score
3 / 10
No MOAT
Composite Rating
C
Overall Score
2 / 5
Medium
DCF Score
2 / 5
Medium
ROE Score
1 / 5
Low
ROA Score
1 / 5
Low
D/E Score
4 / 5
High
P/E Score
1 / 5
Low
P/Book Score
2 / 5
Medium
Operational MOAT
✗ Below peers
-
Revenue growth Biotechnology: +1.6%—
-
EPS growth Biotechnology: +29.7%-28.7% Q1'26: +29.6% (vs Q1'25)
-
FCF margin FCF growth · Biotechnology: +16.2%—
-
EBIT margin Biotechnology: +0.0%—
-
ROIC Biotechnology: -16.1%— Q1'26: +6,546.2% (vs Q1'25)
-
Share dilution Biotechnology: -3.4%+9.3% Q1'26: +39.4% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×-0.01× Q1'26: -0.01× (vs Q1'25)
Valuation Multiples
From
To
Consensus Estimates
| Metric |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 8 EPS Ana. |
Dec 2027 7 EPS Ana. |
Dec 2028 6 Rev. Ana. 7 EPS Ana. |
Dec 2029 5 Rev. Ana. 2 EPS Ana. |
Dec 2030 3 Rev. Ana. 5 EPS Ana. |
|---|---|---|---|---|---|---|---|
| Revenue |
—
|
—
|
—
— – —
|
—
— – —
|
23.57M
23.57M – 23.57M
|
130.30M
130.30M – 130.30M
+452.8% YoY
|
272.01M
272.01M – 272.01M
+108.8% YoY
|
| EBITDA |
-67.95M
|
-98.06M
|
—
— – —
|
—
— – —
|
—
— – —
|
—
— – —
|
—
— – —
|
| EBIT |
-68.19M
|
-98.06M
|
—
— – —
|
—
— – —
|
—
— – —
|
—
— – —
|
—
— – —
|
| Net Income |
-61.92M
est: -486.68M (+87.3%)
|
-86.97M
est: -86.61M (-0.4%)
|
-103.22M
-111.51M – -94.92M
-19.2% YoY
|
-140.56M
-148.26M – -132.87M
-36.2% YoY
|
-128.79M
-194.36M – -63.21M
+8.4% YoY
|
-112.26M
-112.26M – -112.26M
+12.8% YoY
|
-56.89M
-56.89M – -56.89M
+49.3% YoY
|
| SGA |
10.78M
|
18.90M
|
—
— – —
|
—
— – —
|
—
— – —
|
—
— – —
|
—
— – —
|
| EPS |
-1.85
est: -11.52 (+83.9%)
|
-2.38
est: -2.47 (+3.5%)
|
-2.80
-3.05 – -2.60
-13.7% YoY
|
-3.87
-4.06 – -3.64
-37.9% YoY
|
-4.16
-5.32 – -1.73
-7.6% YoY
|
-3.08
-3.08 – -3.08
+26.0% YoY
|
-1.56
-1.56 – -1.56
+49.3% YoY
|
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-08 | C | 2/5 | 2/5 | 1/5 | 1/5 | 4/5 | 1/5 | 2/5 |
| 2026-05-07 | C | 2/5 | 2/5 | 1/5 | 1/5 | 4/5 | 1/5 | 2/5 |
| 2026-05-06 | C | 2/5 | 2/5 | 1/5 | 1/5 | 4/5 | 1/5 | 2/5 |
| 2026-05-05 | C | 2/5 | 2/5 | 1/5 | 1/5 | 4/5 | 1/5 | 2/5 |
| 2026-05-04 | C | 2/5 | 2/5 | 1/5 | 1/5 | 4/5 | 1/5 | 2/5 |
| 2026-05-01 | C | 2/5 | 2/5 | 1/5 | 1/5 | 3/5 | 1/5 | 2/5 |
| 2026-04-30 | C | 2/5 | 2/5 | 1/5 | 1/5 | 3/5 | 1/5 | 2/5 |
| 2026-04-29 | C | 2/5 | 2/5 | 1/5 | 1/5 | 3/5 | 1/5 | 2/5 |
| 2026-04-28 | C | 2/5 | 2/5 | 1/5 | 1/5 | 3/5 | 1/5 | 2/5 |
| 2026-04-27 | C | 2/5 | 2/5 | 1/5 | 1/5 | 3/5 | 1/5 | 2/5 |
| 2026-04-24 | C | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 2/5 |
| 2026-04-23 | C | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-22 | C | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-21 | C | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-20 | C | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-17 | C | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-16 | C | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-15 | C | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
Owner Earnings
Owner's Earnings (history)
Owner's Earnings history not available.
Owner alignment
Owner's Earnings TTM
—
OE per share TTM
—
Owner's Yield
—
Maintenance CapEx ratio
—
Maint CapEx / Avg PPE
—
Ownership Overview
Ownership breakdown
At a glance
Institutional holders
28
Total invested
67.00M
Insider transactions (90d)
3
Beneficial owners (>5%)
47
Beneficial owners (>5%)
| # | Reporting person | Amount owned | % of class | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Type | Citizenship | Filing date | SEC filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | James N. Topper | 5.99M | 18.80% | — | 5.99M | — | 5.99M | IN | — | 2024-09-23 | ↗ |
| 2 | Patrick J. Heron | 5.99M | 18.80% | — | 5.99M | — | 5.99M | IN | — | 2024-09-23 | ↗ |
| 3 | FHMLS X, L.L.C. | 4.55M | 14.30% | — | 4.55M | — | 4.55M | OO | — | 2024-09-23 | ↗ |
| 4 | FHMLS X, L.P. | 4.55M | 14.30% | — | 4.55M | — | 4.55M | PN | — | 2024-09-23 | ↗ |
| 5 | Frazier Life Sciences X, L.P. | 4.55M | 14.30% | — | 4.55M | — | 4.55M | PN | — | 2024-09-23 | ↗ |
| 6 | OrbiMed Advisors LLC | 3.81M | 12.00% | — | 3.81M | — | 10.00 | IA | Delaware | 2024-09-23 | ↗ |
| 7 | Ali Behbahani | 3.61M | 11.40% | — | 3.61M | — | 3.61M | IN | States | 2024-09-23 | ↗ |
| 8 | Anthony A. Florence, Jr. | 3.61M | 11.40% | — | 3.61M | — | 3.61M | IN | States | 2024-09-23 | ↗ |
| 9 | Baskett | 3.61M | 11.40% | — | 3.61M | — | 3.61M | IN | States | 2024-09-23 | ↗ |
| 10 | Carmen Chang | 3.61M | 11.40% | — | 3.61M | — | 3.61M | IN | States | 2024-09-23 | ↗ |
| 11 | D. Sandell | 3.61M | 11.40% | — | 3.61M | — | 3.61M | IN | States | 2024-09-23 | ↗ |
| 12 | Edward T. Mathers | 3.61M | 11.40% | — | 3.61M | — | 3.61M | IN | States | 2024-09-23 | ↗ |
| 13 | Mohamad H. Makhzoumi | 3.61M | 11.40% | — | 3.61M | — | 3.61M | IN | States | 2024-09-23 | ↗ |
| 14 | NEA 17 GP, LLC | 3.61M | 11.40% | — | 3.61M | — | 3.61M | OO | Delaware | 2024-09-23 | ↗ |
| 15 | NEA Partners 17, L.P. | 3.61M | 11.40% | — | 3.61M | — | 3.61M | PN | Delaware | 2024-09-23 | ↗ |
| 16 | New Enterprise Associates 17, L.P. | 3.61M | 11.40% | — | 3.61M | — | 3.61M | PN | Delaware | 2024-09-23 | ↗ |
| 17 | Paul Walker | 3.61M | 11.40% | — | 3.61M | — | 3.61M | IN | States | 2024-09-23 | ↗ |
| 18 | Rick Yang | 3.61M | 11.40% | — | 3.61M | — | 3.61M | IN | States | 2024-09-23 | ↗ |
| 19 | OrbiMed Capital GP VII LLC | 3.16M | 9.90% | — | 3.16M | — | 10.00 | OO | Delaware | 2024-09-23 | ↗ |
| 20 | David Kroin | 3.02M | 9.48% | — | 3.02M | — | — | HC, IN | Delaware | 2024-09-23 | ↗ |
| 21 | Deep Track Biotechnology Master Fund, Ltd. | 3.02M | 9.48% | — | 3.02M | — | — | CO | Delaware | 2024-09-23 | ↗ |
| 22 | Deep Track Capital, LP | 3.02M | 9.48% | — | 3.02M | — | — | IA, OO | Delaware | 2024-09-23 | ↗ |
| 23 | Wellington Group Holdings LLP | 2.94M | 9.22% | — | 2.79M | — | — | HC | Massachusetts | 2024-11-08 | ↗ |
| 24 | Wellington Investment Advisors Holdings LLP | 2.94M | 9.22% | — | 2.79M | — | — | HC | Massachusetts | 2024-11-08 | ↗ |
| 25 | Wellington Management Group LLP | 2.94M | 9.22% | — | 2.79M | — | — | HC | Massachusetts | 2024-11-08 | ↗ |
| 26 | Wellington Management Company LLP | 2.92M | 9.17% | — | 2.79M | — | — | IA | Massachusetts | 2024-11-08 | ↗ |
| 27 | Genesis VC Partners XVI, LLC | 2.14M | 6.40% | — | 2.14M | — | 10.00 | OO | Delaware | 2024-09-23 | ↗ |
| 28 | Jeffrey Crowe | 2.14M | 6.40% | — | 2.14M | — | 10.00 | IN | United States | 2024-09-23 | ↗ |
| 29 | Jon E. Kossow | 2.14M | 6.40% | — | 2.14M | — | 10.00 | IN | United States | 2024-09-23 | ↗ |
| 30 | NVP Associates, LLC | 2.14M | 6.40% | — | 2.14M | — | 10.00 | OO | Delaware | 2024-09-23 | ↗ |
| 31 | Norwest Venture Partners XVI, LP | 2.14M | 6.40% | — | 2.14M | — | 10.00 | PN | Delaware | 2024-09-23 | ↗ |
| 32 | Tiba Aynechi | 2.14M | 6.40% | — | 2.14M | — | 10.00 | IN | United States | 2024-09-23 | ↗ |
| 33 | P. Kent Hawryluk | 1.91M | 5.55% | 1.91M | — | 1.91M | — | IN | United States of America | 2024-11-01 | ↗ |
| 34 | Wellington Biomedical Innovation Master Investors (Cayman) II, L.P. | 1.79M | 5.62% | — | 1.79M | — | — | PN | — | 2024-09-20 | ↗ |
| 35 | Albert Cha | 1.43M | 4.50% | — | 1.43M | — | 1.43M | IN | — | 2024-09-23 | ↗ |
| 36 | James Brush | 1.43M | 4.50% | — | 1.43M | — | 1.43M | IN | — | 2024-09-23 | ↗ |
| 37 | FHMLSP, L.L.C. | 1.10M | 3.50% | — | 1.10M | — | 1.10M | OO | — | 2024-09-23 | ↗ |
| 38 | FHMLSP, L.P. | 1.10M | 3.50% | — | 1.10M | — | 1.10M | PN | — | 2024-09-23 | ↗ |
| 39 | Frazier Life Sciences Public Fund, L.P. | 1.10M | 3.50% | — | 1.10M | — | 1.10M | PN | — | 2024-09-23 | ↗ |
| 40 | OrbiMed Genesis GP LLC | 653.8K | 2.10% | — | 653.8K | — | 10.00 | OO | Delaware | 2024-09-23 | ↗ |
| 41 | FHMLSP Overage, L.L.C. | 325.7K | 1.00% | — | 325.7K | — | 325.7K | OO | — | 2024-09-23 | ↗ |
| 42 | FHMLSP Overage, L.P. | 325.7K | 1.00% | — | 325.7K | — | 325.7K | PN | — | 2024-09-23 | ↗ |
| 43 | Frazier Life Sciences Public Overage Fund, L.P. | 325.7K | 1.00% | — | 325.7K | — | 325.7K | PN | — | 2024-09-23 | ↗ |
| 44 | Daniel Estes | 3.0K | 0.00% | — | 3.0K | — | 3.0K | IN | — | 2024-09-23 | ↗ |
| 45 | FHMLS XI, L.L.C. | 3.0K | 0.00% | — | 3.0K | — | 3.0K | OO | — | 2024-09-23 | ↗ |
| 46 | FHMLS XI, L.P. | 3.0K | 0.00% | — | 3.0K | — | 3.0K | PN | — | 2024-09-23 | ↗ |
| 47 | Frazier Life Sciences XI, L.P. | 3.0K | 0.00% | — | 3.0K | — | 3.0K | PN | — | 2024-09-23 | ↗ |
Institutional Activity (13F)
Institutional ownership trend
From
To
13F snapshot — 2026 Q1
Investors holding
28
-116 vs prev Q
New positions
7
Closed positions
118
Increased
14
Reduced
7
Put/Call ratio
0.00
Calls held
—
Puts held
—
Top institutional holders
| # | Investor | Shares / Δ | Mkt value / Δ | Own% / Δ | Weight% / Δ | Avg px / Perf. | Hold / Status |
|---|---|---|---|---|---|---|---|
| 1 | — | 315.2K +315.2K (+100.0%) | 9.94B +9.9B (+100.0%) | 0.92% +0.922 pp | 2.46% +2.456 pp | USD31.54 +0.0% | 1 qtrs NEW |
| 2 | FRAZIER LIFE SCIENCES MANAGEMENT, L.P. | 6.65M +— (+0.0%) | 209.80M +93.4M (+80.2%) | 19.45% +0.000 pp | 5.64% +2.147 pp | USD25.13 +25.5% | 6 qtrs — |
| 3 | ORBIMED ADVISORS LLC | 3.94M -67.7K (-1.7%) | 124.12M +54.1M (+77.2%) | 11.51% -0.198 pp | 2.54% +0.893 pp | USD25.09 +25.7% | 6 qtrs — |
| 4 | NEA MANAGEMENT COMPANY, LLC | 3.61M +— (+0.0%) | 114.00M +50.7M (+80.2%) | 10.57% +0.000 pp | 5.81% +2.342 pp | USD25.98 +21.4% | 6 qtrs — |
| 5 | WELLINGTON MANAGEMENT GROUP LLP | 3.35M -1.5M (-30.5%) | 105.66M +21.2M (+25.2%) | 9.80% -4.308 pp | 0.02% +0.004 pp | USD21.49 +46.8% | 6 qtrs — |
| 6 | DEEP TRACK CAPITAL, LP | 3.25M +99.8K (+3.2%) | 102.50M +47.4M (+85.9%) | 9.50% +0.292 pp | 1.83% +0.289 pp | USD23.64 +33.4% | 6 qtrs — |
| 7 | BLACKROCK, INC. | 2.92M +962.3K (+49.2%) | 92.09M +57.8M (+168.8%) | 8.54% +2.814 pp | 0.00% +0.001 pp | USD21.69 +45.4% | 5 qtrs — |
| 8 | NVP ASSOCIATES, LLC | 2.14M +— (+0.0%) | 67.38M +30.0M (+80.2%) | 6.25% +0.000 pp | 26.40% +3.887 pp | USD25.98 +21.4% | 6 qtrs — |
| 9 | ECOR1 CAPITAL, LLC | 2.12M +— (+0.0%) | 66.98M +29.8M (+80.2%) | 6.21% +0.000 pp | 3.04% +1.256 pp | USD21.82 +44.5% | 6 qtrs — |
| 10 | VANGUARD GROUP INC | 1.82M +140.4K (+8.4%) | 57.33M +28.0M (+95.3%) | 5.32% +0.411 pp | 0.00% +0.000 pp | USD17.86 +76.6% | 6 qtrs — |
| 11 | DRIEHAUS CAPITAL MANAGEMENT LLC | 1.41M -131.5K (-8.5%) | 44.41M +17.5M (+64.8%) | 4.12% -0.385 pp | 0.30% +0.109 pp | USD23.11 +36.5% | 6 qtrs — |
| 12 | CORMORANT ASSET MANAGEMENT, LP | 1.12M -105.0K (-8.6%) | 35.32M +13.9M (+64.8%) | 3.28% -0.307 pp | 1.63% +0.154 pp | USD22.35 +41.1% | 6 qtrs — |
| 13 | BRAIDWELL LP | 1.02M +1.0M (+100.0%) | 32.13M +32.1M (+100.0%) | 2.98% +2.979 pp | 1.03% +1.027 pp | USD31.54 +0.0% | 1 qtrs NEW |
| 14 | WOODLINE PARTNERS LP | 1.00M -201.1K (-16.7%) | 31.54M +10.5M (+50.1%) | 2.92% -0.588 pp | 0.12% +0.023 pp | USD18.85 +67.3% | 6 qtrs — |
| 15 | KYNAM CAPITAL MANAGEMENT, LP | 934.8K -1.1M (-53.3%) | 29.48M -5.5M (-15.8%) | 2.73% -3.115 pp | 1.88% -0.723 pp | USD17.50 +80.2% | 2 qtrs — |
| 16 | EVENTIDE ASSET MANAGEMENT, LLC | 890.0K +890.0K (+100.0%) | 28.07M +28.1M (+100.0%) | 2.60% +2.602 pp | 0.44% +0.439 pp | USD31.54 +0.0% | 1 qtrs NEW |
| 17 | PARKMAN HEALTHCARE PARTNERS LLC | 885.6K +112.3K (+14.5%) | 27.93M +14.4M (+106.4%) | 2.59% +0.329 pp | 2.66% +1.248 pp | USD14.52 +117.2% | 5 qtrs — |
| 18 | PRICE T ROWE ASSOCIATES INC /MD/ | 840.5K -114.2K (-12.0%) | 26.51M +9.8M (+58.7%) | 2.46% -0.334 pp | 0.00% +0.001 pp | USD23.32 +35.2% | 6 qtrs — |
| 19 | CITADEL ADVISORS LLC | 809.9K -186.2K (-18.7%) | 25.54M +8.1M (+46.5%) | 2.37% -0.545 pp | 0.00% +0.001 pp | USD17.50 +80.2% | 2 qtrs — |
| 20 | POINT72 ASSET MANAGEMENT, L.P. | 680.6K +52.9K (+8.4%) | 21.47M +10.5M (+95.4%) | 1.99% +0.155 pp | 0.02% +0.006 pp | USD12.55 +151.3% | 6 qtrs — |
| 21 | STATE STREET CORP | 672.7K +353.5K (+110.7%) | 21.22M +15.6M (+279.8%) | 1.97% +1.034 pp | 0.00% +0.001 pp | USD23.76 +32.7% | 5 qtrs — |
| 22 | D. E. SHAW & CO., INC. | 671.8K +671.8K (+100.0%) | 21.19M +21.2M (+100.0%) | 1.96% +1.965 pp | 0.01% +0.012 pp | USD31.54 +0.0% | 1 qtrs NEW |
| 23 | TCG CROSSOVER MANAGEMENT, LLC | 650.0K +— (+0.0%) | 20.50M +9.1M (+80.2%) | 1.90% +0.000 pp | 0.68% +0.119 pp | USD25.98 +21.4% | 6 qtrs — |
| 24 | GEODE CAPITAL MANAGEMENT, LLC | 649.4K +175.5K (+37.0%) | 20.49M +12.2M (+146.9%) | 1.90% +0.513 pp | 0.00% +0.001 pp | USD21.10 +49.5% | 6 qtrs — |
| 25 | MILLENNIUM MANAGEMENT LLC | 462.0K -193.4K (-29.5%) | 14.57M +3.1M (+27.1%) | 1.35% -0.565 pp | 0.01% +0.001 pp | USD14.65 +115.3% | 6 qtrs — |
| 26 | SOLEUS CAPITAL MANAGEMENT, L.P. | 408.9K +133.9K (+48.7%) | 12.90M +8.1M (+168.0%) | 1.20% +0.392 pp | 0.48% +0.234 pp | USD22.10 +42.7% | 2 qtrs — |
| 27 | GOLDMAN SACHS GROUP INC | 331.9K -26.2K (-7.3%) | 10.47M +4.2M (+67.1%) | 0.97% -0.077 pp | 0.00% +0.001 pp | USD17.50 +80.2% | 6 qtrs — |
| 28 | ROCK SPRINGS CAPITAL MANAGEMENT LP | 282.6K +— (+0.0%) | 8.91M +4.0M (+80.2%) | 0.83% +0.000 pp | 0.46% +0.168 pp | USD17.50 +80.2% | 2 qtrs — |
| 29 | UBS GROUP AG | 281.2K +220.5K (+363.1%) | 8.87M +7.8M (+734.6%) | 0.82% +0.645 pp | 0.00% +0.001 pp | USD28.52 +10.6% | 5 qtrs — |
| 30 | OPALEYE MANAGEMENT INC. | 260.0K +7.0K (+2.8%) | 8.20M +3.8M (+85.2%) | 0.76% +0.021 pp | 1.08% +0.456 pp | USD8.56 +268.5% | 4 qtrs — |
| 31 | AFFINITY ASSET ADVISORS, LLC | 250.0K +85.0K (+51.5%) | 7.89M +5.0M (+173.1%) | 0.73% +0.249 pp | 0.45% +0.198 pp | USD22.27 +41.6% | 4 qtrs — |
| 32 | SUSQUEHANNA INTERNATIONAL GROUP, LLP | 228.0K -258.8K (-53.2%) | 7.19M -1.3M (-15.6%) | 0.67% -0.757 pp | 0.00% 0.000 pp | USD16.79 +87.8% | 3 qtrs — |
| 33 | CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 222.2K +52.2K (+30.7%) | 7.01M +4.0M (+135.5%) | 0.65% +0.153 pp | 0.00% +0.001 pp | USD20.78 +51.8% | 5 qtrs — |
| 34 | GOELZER INVESTMENT MANAGEMENT, INC. | 221.7K +221.7K (+100.0%) | 6.99M +7.0M (+100.0%) | 0.65% +0.648 pp | 0.32% +0.324 pp | USD31.54 +0.0% | 1 qtrs NEW |
| 35 | NORTHERN TRUST CORP | 190.9K +57.6K (+43.2%) | 6.02M +3.7M (+158.1%) | 0.56% +0.169 pp | 0.00% +0.001 pp | USD21.26 +48.4% | 5 qtrs — |
| 36 | SCHONFELD STRATEGIC ADVISORS LLC | 167.1K -115.6K (-40.9%) | 5.27M +324.3K (+6.6%) | 0.49% -0.338 pp | 0.02% -0.005 pp | USD11.38 +177.2% | 5 qtrs — |
| 37 | DAFNA CAPITAL MANAGEMENT LLC | 165.3K +80.3K (+94.4%) | 5.21M +3.7M (+250.4%) | 0.48% +0.235 pp | 1.21% +0.843 pp | USD24.32 +29.7% | 2 qtrs — |
| 38 | 683 CAPITAL MANAGEMENT, LLC | 158.8K -125.0K (-44.0%) | 5.01M +42.1K (+0.8%) | 0.46% -0.366 pp | 0.22% -0.042 pp | USD17.50 +80.2% | 2 qtrs — |
| 39 | TFG ASSET MANAGEMENT GP LTD | 143.3K -34.5K (-19.4%) | 4.52M +1.4M (+45.3%) | 0.42% -0.101 pp | 0.95% +0.537 pp | USD17.50 +80.2% | 2 qtrs — |
| 40 | TWO SIGMA INVESTMENTS, LP | 138.6K +125.0K (+919.9%) | 4.37M +4.1M (+1,738.1%) | 0.41% +0.366 pp | 0.01% +0.006 pp | USD30.16 +4.6% | 4 qtrs — |
| 41 | BALYASNY ASSET MANAGEMENT L.P. | 119.7K +94.1K (+366.9%) | 3.78M +3.3M (+741.5%) | 0.35% +0.275 pp | 0.00% +0.004 pp | USD28.53 +10.6% | 2 qtrs — |
| 42 | TD ASSET MANAGEMENT INC | 101.5K -17.3K (-14.6%) | 3.20M +1.1M (+53.9%) | 0.30% -0.051 pp | 0.00% +0.001 pp | USD11.82 +166.8% | 6 qtrs — |
| 43 | BURKEHILL GLOBAL MANAGEMENT, LP | 100.0K +— (+0.0%) | 3.15M +1.4M (+80.2%) | 0.29% +0.000 pp | 0.21% +0.108 pp | USD17.50 +80.2% | 2 qtrs — |
| 44 | JANE STREET GROUP, LLC | 86.6K +86.6K (+100.0%) | 2.73M +2.7M (+100.0%) | 0.25% +0.253 pp | 0.00% +0.000 pp | USD31.54 +0.0% | 1 qtrs NEW |
| 45 | PFM HEALTH SCIENCES, LP | 79.3K -142.2K (-64.2%) | 2.50M -1.4M (-35.5%) | 0.23% -0.416 pp | 0.25% -0.049 pp | USD17.50 +80.2% | 2 qtrs — |
| 46 | STEMPOINT CAPITAL LP | 78.6K +3.6K (+4.7%) | 2.48M +1.2M (+88.8%) | 0.23% +0.010 pp | 0.42% +0.162 pp | USD9.68 +225.8% | 6 qtrs — |
| 47 | ADVISOR GROUP HOLDINGS, INC. | 77.6K +77.6K (+100.0%) | 2.45M +2.4M (+100.0%) | 0.23% +0.227 pp | 0.00% +0.004 pp | USD31.54 +0.0% | 1 qtrs NEW |
| 48 | NUVEEN, LLC | 75.6K +53.4K (+241.3%) | 2.38M +2.0M (+515.0%) | 0.22% +0.156 pp | 0.00% +0.001 pp | USD24.87 +26.8% | 4 qtrs — |
| 49 | BANK OF NEW YORK MELLON CORP | 75.3K +27.5K (+57.7%) | 2.37M +1.5M (+184.2%) | 0.22% +0.081 pp | 0.00% +0.000 pp | USD21.79 +44.7% | 5 qtrs — |
| 50 | SCHRODER INVESTMENT MANAGEMENT GROUP | 73.7K -10.0K (-12.0%) | 2.28M +775.7K (+51.6%) | 0.22% -0.029 pp | 0.00% +0.001 pp | USD17.50 +80.2% | 2 qtrs — |
| 51 | AARON WEALTH ADVISORS LLC | 70.0K +20.0K (+40.0%) | 2.21M +1.3M (+152.3%) | 0.20% +0.059 pp | 0.12% +0.069 pp | USD14.28 +120.9% | 4 qtrs — |
| 52 | MANUFACTURERS LIFE INSURANCE COMPANY, THE | 69.6K +1.2K (+1.7%) | 2.15M +958.2K (+80.1%) | 0.20% +0.003 pp | 0.00% +0.001 pp | USD19.60 +60.9% | 6 qtrs — |
| 53 | MORGAN STANLEY | 59.0K +14.2K (+31.6%) | 1.86M +1.1M (+137.1%) | 0.17% +0.041 pp | 0.00% +0.000 pp | USD17.69 +78.3% | 5 qtrs — |
| 54 | VERITION FUND MANAGEMENT LLC | 57.6K +57.6K (+100.0%) | 1.82M +1.8M (+100.0%) | 0.17% +0.168 pp | 0.01% +0.007 pp | USD31.54 +0.0% | 1 qtrs NEW |
| 55 | EXODUSPOINT CAPITAL MANAGEMENT, LP | 57.0K -43.0K (-43.0%) | 1.80M +47.9K (+2.7%) | 0.17% -0.126 pp | 0.01% -0.004 pp | USD17.50 +80.2% | 2 qtrs — |
| 56 | BARCLAYS PLC | 52.7K +36.3K (+221.3%) | 1.66M +1.2M (+290.0%) | 0.15% +0.105 pp | 0.00% +0.000 pp | USD26.16 +20.6% | 6 qtrs — |
| 57 | ACADIAN ASSET MANAGEMENT LLC | 48.6K +43.6K (+870.5%) | 1.53M +1.4M (+1,679.1%) | 0.14% +0.128 pp | 0.00% +0.002 pp | USD30.09 +4.8% | 2 qtrs — |
| 58 | SQUAREPOINT OPS LLC | 46.7K +46.7K (+100.0%) | 1.47M +1.5M (+100.0%) | 0.14% +0.137 pp | 0.00% +0.002 pp | USD31.54 +0.0% | 1 qtrs NEW |
| 59 | PLATINUM INVESTMENT MANAGEMENT LTD | 43.6K -25.8K (-37.2%) | 1.38M +160.1K (+13.2%) | 0.13% -0.076 pp | 0.32% +0.239 pp | USD23.10 +36.5% | 6 qtrs — |
| 60 | BANK OF AMERICA CORP /DE/ | 37.9K +11.3K (+42.4%) | 1.20M +729.4K (+156.6%) | 0.11% +0.031 pp | 0.00% +0.000 pp | USD18.47 +70.8% | 5 qtrs — |
| 61 | ALPS ADVISORS INC | 36.9K +20.0K (+119.0%) | 1.16M +868.2K (+294.6%) | 0.11% +0.059 pp | 0.01% +0.005 pp | USD25.55 +23.4% | 5 qtrs — |
| 62 | CREATIVE PLANNING | 33.7K +4.9K (+17.1%) | 1.06M +558.5K (+111.1%) | 0.10% +0.014 pp | 0.00% +0.000 pp | USD19.55 +61.3% | 2 qtrs — |
| 63 | RHUMBLINE ADVISERS | 33.4K +11.6K (+53.2%) | 1.05M +672.2K (+176.0%) | 0.10% +0.034 pp | 0.00% +0.001 pp | USD20.08 +57.1% | 5 qtrs — |
| 64 | RENAISSANCE TECHNOLOGIES LLC | 32.6K +32.6K (+100.0%) | 1.03M +1.0M (+100.0%) | 0.10% +0.096 pp | 0.00% +0.002 pp | USD31.54 +0.0% | 1 qtrs NEW |
| 65 | WELLS FARGO & COMPANY/MN | 31.9K +20.2K (+171.6%) | 1.01M +801.4K (+389.6%) | 0.09% +0.059 pp | 0.00% +0.000 pp | USD25.55 +23.4% | 5 qtrs — |
| 66 | AQR CAPITAL MANAGEMENT LLC | 31.4K +15.6K (+99.2%) | 990.6K +714.8K (+259.1%) | 0.09% +0.046 pp | 0.00% +0.000 pp | USD21.44 +47.1% | 3 qtrs — |
| 67 | ALLIANCEBERNSTEIN L.P. | 27.9K +17.4K (+165.7%) | 880.0K +696.2K (+378.9%) | 0.08% +0.051 pp | 0.00% +0.000 pp | USD23.96 +31.6% | 3 qtrs — |
| 68 | BREVAN HOWARD CAPITAL MANAGEMENT LP | 25.7K +25.7K (+100.0%) | 809.4K +809.4K (+100.0%) | 0.08% +0.075 pp | 0.01% +0.009 pp | USD31.54 +0.0% | 1 qtrs NEW |
| 69 | CAPTION MANAGEMENT, LLC | 25.1K -49.9K (-66.5%) | 791.7K -520.8K (-39.7%) | 0.07% -0.146 pp | 0.01% -0.005 pp | USD17.50 +80.2% | 2 qtrs — |
| 70 | TREXQUANT INVESTMENT LP | 24.3K +24.3K (+100.0%) | 765.4K +765.4K (+100.0%) | 0.07% +0.071 pp | 0.01% +0.007 pp | USD31.54 +0.0% | 1 qtrs NEW |
| 71 | FOX RUN MANAGEMENT, L.L.C. | 23.8K +23.8K (+100.0%) | 751.3K +751.3K (+100.0%) | 0.07% +0.070 pp | 0.12% +0.116 pp | USD31.54 +0.0% | 1 qtrs NEW |
| 72 | QUBE RESEARCH & TECHNOLOGIES LTD | 23.2K +23.2K (+100.0%) | 732.1K +732.1K (+100.0%) | 0.07% +0.068 pp | 0.00% +0.001 pp | USD31.54 +0.0% | 1 qtrs NEW |
| 73 | CERITY PARTNERS LLC | 21.3K +21.3K (+100.0%) | 672.5K +672.5K (+100.0%) | 0.06% +0.062 pp | 0.00% +0.001 pp | USD31.54 +0.0% | 1 qtrs NEW |
| 74 | INVESCO LTD. | 21.2K +9.4K (+79.9%) | 668.7K +462.5K (+224.2%) | 0.06% +0.028 pp | 0.00% +0.000 pp | USD23.73 +32.9% | 2 qtrs — |
| 75 | XTX TOPCO LTD | 20.1K -18.2K (-47.5%) | 635.2K -36.4K (-5.4%) | 0.06% -0.053 pp | 0.02% -0.018 pp | USD15.62 +101.9% | 3 qtrs — |
| 76 | DEUTSCHE BANK AG\ | 20.0K +9.1K (+83.3%) | 631.7K +440.5K (+230.4%) | 0.06% +0.027 pp | 0.00% +0.000 pp | USD21.85 +44.3% | 5 qtrs — |
| 77 | GSA CAPITAL PARTNERS LLP | 19.3K +19.3K (+100.0%) | 609.0K +609.0K (+100.0%) | 0.06% +0.056 pp | 0.05% +0.053 pp | USD31.54 +0.0% | 1 qtrs NEW |
| 78 | KOA WEALTH MANAGEMENT, LLC | 18.4K -8.3K (-31.1%) | 580.7K +113.3K (+24.2%) | 0.05% -0.024 pp | 0.40% +0.052 pp | USD8.95 +252.4% | 4 qtrs — |
| 79 | CITIGROUP INC | 16.4K +16.2K (+9,108.4%) | 517.0K +513.9K (+16,490.9%) | 0.05% +0.047 pp | 0.00% +0.000 pp | USD31.29 +0.8% | 5 qtrs — |
| 80 | METLIFE INVESTMENT MANAGEMENT, LLC | 16.0K +5.0K (+45.4%) | 505.2K +312.4K (+162.0%) | 0.05% +0.015 pp | 0.00% +0.002 pp | USD17.69 +78.3% | 5 qtrs — |
| 81 | FMR LLC | 15.7K -53.2K (-77.2%) | 496.6K -710.5K (-58.9%) | 0.05% -0.156 pp | 0.00% +0.000 pp | USD13.44 +134.7% | 5 qtrs — |
| 82 | CHINA UNIVERSAL ASSET MANAGEMENT CO., LTD. | 15.3K +10.3K (+206.3%) | 483.1K +395.6K (+452.1%) | 0.04% +0.030 pp | 0.04% +0.030 pp | USD26.96 +17.0% | 2 qtrs — |
| 83 | JPMORGAN CHASE & CO | 14.6K +8.5K (+137.2%) | 461.9K +353.8K (+327.4%) | 0.04% +0.024 pp | 0.00% +0.000 pp | USD21.56 +46.3% | 5 qtrs — |
| 84 | MIRAE ASSET GLOBAL ETFS HOLDINGS LTD. | 13.3K +6.1K (+86.2%) | 418.2K +293.6K (+235.6%) | 0.04% +0.018 pp | 0.00% +0.000 pp | USD23.22 +35.8% | 5 qtrs — |
| 85 | AMERICAN CENTURY COMPANIES INC | 12.2K +12.2K (+100.0%) | 385.9K +385.9K (+100.0%) | 0.04% +0.036 pp | 0.00% +0.000 pp | USD31.54 +0.0% | 1 qtrs NEW |
| 86 | CANADA PENSION PLAN INVESTMENT BOARD | 11.6K +11.6K (+100.0%) | 365.9K +365.9K (+100.0%) | 0.03% +0.034 pp | 0.00% +0.000 pp | USD31.54 +0.0% | 1 qtrs NEW |
| 87 | GRAHAM CAPITAL MANAGEMENT, L.P. | 11.3K +11.3K (+100.0%) | 355.0K +355.0K (+100.0%) | 0.03% +0.033 pp | 0.01% +0.009 pp | USD31.54 +0.0% | 1 qtrs NEW |
| 88 | BRIDGEWAY CAPITAL MANAGEMENT, LLC | 10.0K -4.2K (-29.6%) | 315.4K +66.9K (+26.9%) | 0.03% -0.012 pp | 0.01% +0.001 pp | USD11.41 +176.4% | 3 qtrs — |
| 89 | GROUP ONE TRADING, L.P. | 9.4K +9.4K (+100.0%) | 297.4K +297.4K (+100.0%) | 0.03% +0.028 pp | 0.00% +0.001 pp | USD31.54 +0.0% | 1 qtrs NEW |
| 90 | PROFUND ADVISORS LLC | 9.2K +9.2K (+100.0%) | 290.6K +290.6K (+100.0%) | 0.03% +0.027 pp | 0.01% +0.009 pp | USD31.54 +0.0% | 1 qtrs NEW |
| 91 | SIMPLEX TRADING, LLC | 8.9K +8.9K (+100.0%) | 281.5K +281.5K (+100.0%) | 0.03% +0.026 pp | 0.00% +0.000 pp | USD31.54 +0.0% | 3 qtrs — |
| 92 | VIRTUS INVESTMENT ADVISERS, INC. | 8.9K -1.7K (-16.1%) | 281.0K +95.3K (+51.3%) | 0.03% -0.005 pp | 0.08% +0.023 pp | USD9.43 +234.5% | 4 qtrs — |
| 93 | LOS ANGELES CAPITAL MANAGEMENT LLC | 10.4K +10.4K (+100.0%) | 225.7K +225.7K (+100.0%) | 0.03% +0.030 pp | 0.00% +0.001 pp | USD31.54 +0.0% | 1 qtrs NEW |
Ownership breakdown by holder
Insider Activity
Insider Activity — Latest Quarter
Ratio by transactions
1.00
Neutral
Ratio by volume
3.00
Bullish
Buys
2
Sells
2
Shares acquired
86.2K
Shares disposed
838.00
Cash buys
—
Cash sales
2.00
Net activity
+85,349
Insider buys vs sells (history)
From
To
Recent insider transactions
From
To
| Date | Person | Role | Transaction | A/D | Security | Shares | Price | Value | Owned after | D/I | Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-05-06 | Hawryluk P. Kent | Director / Officer | S-Sale | D | Common Stock | 607 | 29.54 | 17.9K | 727,667 | D | ↗ |
| 2026-05-06 | Azoulay Salomon | Officer | S-Sale | D | Common Stock | 231 | 29.54 | 6.8K | 14,769 | D | ↗ |
| 2026-05-01 | Hoerter Steven L. | Director | A-Award | A | Stock option (right to buy) | 74,249 | 29.78 | 2.21M | 74,249 | D | ↗ |
| 2026-03-16 | Smither John W | — | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2026-03-13 | Hawryluk P. Kent | Director / Officer | P-Purchase | A | Common Stock | 18,500 | 28.41 | 525.7K | 486,777 | I | ↗ |
| 2026-02-26 | Hawryluk P. Kent | Director / Officer | M-Exempt | A | Common Stock | 28,768 | 16.00 | 460.3K | 728,274 | D | ↗ |
| 2026-02-02 | Hawryluk P. Kent | Director / Officer | A-Award | A | Common Stock | 35,250 | 0.00 | — | 699,506 | D | ↗ |
| 2026-02-02 | Bartram Richard | Officer | A-Award | A | Stock option (right to buy) | 70,000 | 39.07 | 2.73M | 70,000 | D | ↗ |
| 2026-02-02 | Azoulay Salomon | Officer | A-Award | A | Stock option (right to buy) | 70,000 | 39.07 | 2.73M | 70,000 | D | ↗ |
| 2026-01-20 | Stelzer Laurie | Director | A-Award | A | Stock option (right to buy) | 32,000 | 43.14 | 1.38M | 32,000 | D | ↗ |
| 2025-11-22 | Hoerter Steven L. | Director | A-Award | A | Stock option (right to buy) | 8,000 | 27.08 | 216.6K | 8,000 | D | ↗ |
| 2025-11-06 | Hoerter Steven L. | Director | A-Award | A | Stock option (right to buy) | 100,000 | 24.74 | 2.47M | 100,000 | D | ↗ |
| 2025-10-24 | Hawryluk P. Kent | Director / Officer | M-Exempt | A | Common Stock | 182,859 | 3.25 | 594.3K | 664,256 | D | ↗ |
| 2025-10-20 | Hawryluk P. Kent | Director / Officer | P-Purchase | A | Common Stock | 20,000 | 13.64 | 272.8K | 468,277 | I | ↗ |
| 2025-10-17 | Hoerter Steven L. | Director | P-Purchase | A | Common Stock | 20,000 | 13.25 | 265.0K | 20,000 | I | ↗ |
| 2025-09-26 | Heron Patrick J | Director / 10% Owner | P-Purchase | A | Common Stock | 666,666 | 18.00 | 12.00M | 5,219,440 | I | ↗ |
| 2025-06-05 | Ryder Steven | Director | A-Award | A | Stock option (right to buy) | 16,000 | 11.86 | 189.8K | 16,000 | D | ↗ |
| 2025-06-05 | Pescovitz Ora H. | Director | A-Award | A | Stock option (right to buy) | 16,000 | 11.86 | 189.8K | 16,000 | D | ↗ |
| 2025-06-05 | Mathers Edward T | Director / 10% Owner | A-Award | A | Stock option (right to buy) | 16,000 | 11.86 | 189.8K | 16,000 | D | ↗ |
| 2025-06-05 | Hoerter Steven L. | Director | A-Award | A | Stock option (right to buy) | 16,000 | 11.86 | 189.8K | 16,000 | D | ↗ |
| 2025-06-05 | Heron Patrick J | Director / 10% Owner | A-Award | A | Stock option (right to buy) | 16,000 | 11.86 | 189.8K | 16,000 | D | ↗ |
| 2025-06-05 | CORNELIUS JAMES M | Director | A-Award | A | Stock option (right to buy) | 16,000 | 11.86 | 189.8K | 16,000 | D | ↗ |
| 2025-06-05 | Aynechi Tiba | Director | A-Award | A | Stock option (right to buy) | 16,000 | 11.86 | 189.8K | 16,000 | D | ↗ |
| 2025-04-08 | Pescovitz Ora H. | Director | P-Purchase | A | Common Stock | 7,693 | 5.89 | 45.3K | 24,329 | D | ↗ |
| 2025-04-07 | Hoerter Steven L. | Director | A-Award | A | Stock option (right to buy) | 32,000 | 6.00 | 192.0K | 32,000 | D | ↗ |
Executive team
Top executives
Shares Outstanding
33.59M
Executive compensation
Executive compensation (annual)
| # | Year | Executive | Salary | Bonus | Stock award | Option award | Incentive | Other | Total | % Stock- based |
Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 2025 | P. Kent Hawryluk President and Chief Executive Officer | 625.0K | — | — | 2.00M | 359.4K | 8.4K | 2.99M | 66.81% | ↗ |
| 2 | 2025 | Richard Bartram Former Chief Financial Officer | 484.0K | — | — | 781.1K | 222.6K | 8.5K | 1.50M | 52.21% | ↗ |
| 3 | 2025 | Salomon Azoulay, M.D. Chief Medical Officer | 488.5K | — | — | 740.0K | 235.9K | 10.5K | 1.47M | 50.17% | ↗ |
| 4 | 2024 | Salomon Azoulay, M.D. Chief Medical Officer | 234.4K | 25.0K | — | 2.74M | 93.8K | — | 3.10M | 88.59% | ↗ |
| 5 | 2024 | Salomon Azoulay, M.D. Chief Medical Officer | 234.4K | 25.0K | — | 2.74M | 93.8K | — | 3.10M | 88.59% | ↗ |
| 6 | 2024 | P. Kent Hawryluk President and Chief Executive Officer | 483.3K | — | — | 1.45M | 305.0K | — | 2.24M | 64.73% | ↗ |
| 7 | 2024 | P. Kent Hawryluk President and Chief Executive Officer | 483.3K | — | — | 1.45M | 305.0K | — | 2.24M | 64.73% | ↗ |
| 8 | 2024 | Richard Bartram Former Chief Financial Officer | 442.0K | — | — | 511.6K | 200.0K | — | 1.15M | 44.35% | ↗ |
| 9 | 2024 | Richard Bartram Chief Financial Officer | 442.0K | — | — | 511.6K | 200.0K | — | 1.15M | 44.35% | ↗ |
| 10 | 2023 | P. Kent Hawryluk President and Chief Executive Officer | 420.0K | — | — | 4.29M | 151.2K | — | 4.86M | 88.25% | ↗ |
| 11 | 2023 | Richard Bartram Chief Financial Officer | 425.0K | — | — | 473.1K | 153.0K | — | 1.05M | 45.01% | ↗ |
CEO compensation breakdown
Proxy statements
Proxy statements (DEF 14A)
Recent SEC filings
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Peter Kent Hawryluk | Chief Executive Officer, President & Director | 992.8K | male |
| Salomon Azoulay | Chief Medical Officer | 734.9K | — |
| Richard Bartram | Chief Financial Officer | 642.0K | male |
| Steven L. Hoerter | Executive Chairperson | 40.5K | male |
| Mark Hope | Senior Vice President of Regulatory & Quality | — | male |
| Michael A. Dorato DABT | Sr. Vice President of Discovery & Non-Clinical Development | — | — |
| Andreas Moraitis | Senior Vice President of Clinical Development | — | — |
| Pete De Spain | Senior Vice President of Investor Relations & Corporate Communications | — | male |
| Michelle Graham | Chief Human Resources Officer | — | female |
| Chatan Charan | Senior Vice President of Pharmaceutical Development & Chemistry, Manufacturing and Controls | — | — |
| John W. Smither | Interim Chief Financial Officer | — | male |
| Karen Basbaum | Chief Business Officer | — | female |
ESG Rating
ESG Score History BIOTECHNOLOGY
Benchmark vs Sector
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for MBX
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
